Home » Stocks » GRAY

Graybug Vision, Inc. (GRAY)

Stock Price: $4.38 USD 0.11 (2.58%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $4.47 +0.09 (2.06%) May 7, 7:59 PM
Market Cap 90.54M
Revenue (ttm) n/a
Net Income (ttm) -34.72M
Shares Out 21.06M
EPS (ttm) -5.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $4.38
Previous Close $4.27
Change ($) 0.11
Change (%) 2.58%
Day's Open 4.30
Day's Range 4.23 - 4.49
Day's Volume 611,155
52-Week Range 3.96 - 37.88

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Graybug Vision Inc (NASDAQ: GRAY) shares are dropping after preliminary data from Phase 2b ALTISSIMO trial of GB-102 for wet age-related macular degeneration (wet AMD). Investors are reacting to the mea...

1 month ago - Benzinga

REDWOOD CITY, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment ...

1 month ago - GlobeNewsWire

REDWOOD CITY, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment ...

2 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vi...

2 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vi...

3 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vi...

4 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment o...

5 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment o...

5 months ago - GlobeNewsWire

U.S. IPO Weekly Recap: Health And Tech Dominate The Calendar In An 11 IPO Week

Other stocks mentioned: AMST, BSY, CRSR, FCACU, GDRX, GLSI, LSF ...
7 months ago - Seeking Alpha

Graybug Vision Inc.'s stock started its public life with a rally, as it opened 18.8% above its initial public offering price. The first trade was at $19.00 at 12:15 p.m.

7 months ago - Market Watch

REDWOOD CITY, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic...

7 months ago - GlobeNewsWire

Graybug Vision Inc. GRAY, +2.59% said early Friday that its upsized initial public offering priced at $16 a share, in the middle of the expected range of $15 to $17 a share.

7 months ago - Market Watch

REDWOOD CITY, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic...

7 months ago - GlobeNewsWire

Graybug Vision has filed to raise $75 million from the sale of its common stock in a U.S. IPO.

7 months ago - Seeking Alpha

About GRAY

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopath... [Read more...]

Industry
Biotechnology
IPO Date
Sep 25, 2020
Stock Exchange
NASDAQ
Ticker Symbol
GRAY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Graybug Vision stock is "Strong Buy." The 12-month stock price forecast is 14.00, which is an increase of 219.63% from the latest price.

Price Target
$14.00
(219.63% upside)
Analyst Consensus: Strong Buy